OncoMatch/Clinical Trials/NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Is NCT07011719 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Casdatifan and Cabozantinib for metastatic clear cell renal cell carcinoma.
Treatment: Casdatifan · Cabozantinib — The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Renal Cell Carcinoma
Prior therapy
Cannot have received: hif-2α inhibitor
Cannot have received: cabozantinib (cabozantinib)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and marrow function, ≤ 1 week prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Gilbert, Arizona
- Research Site · Goodyear, Arizona
- Research Site · Phoenix, Arizona
- Research Site · Duarte, California
- Research Site · La Jolla, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07011719 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hif-2α inhibitor, cabozantinib disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages